Ramaphosa's energy plan Webinar banner

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

UK's speedy COVID-19 vaccine roll out hit by supply cut

Newsdeck

Newsdeck

UK’s speedy COVID-19 vaccine roll out hit by supply cut

Health Workers receive the COVID-19 vaccine at George Mukhari Hospital on March 03, 2021 in Pretoria, South Africa. (Photo: Gallo Images/Lefty Shivambu)
By Reuters
17 Mar 2021 0

LONDON, March 17 (Reuters) - Britain will see a significant reduction in the amount of COVID-19 vaccines available at the end of the month due to a cut in manufacturing supply, it said on Wednesday, in a setback to one of the fastest rollouts in the world. Britain is on track to have given a first COVID-19 shot to half of all adults in the next few days and passed 25 million first shots on Wednesday, making it the most extensive and quickest programme so far in a European country.

By Alistair Smout and Michael Holden

Health Secretary Matt Hancock said supply often fluctuated but the country remained on track to have given vaccines to priority groups by April 15 and all adults by the end of July.

“Vaccine supply is always lumpy and we regularly send out technical letters to the NHS to explain the ups and downs of the supply over the future weeks,” Hancock told reporters.

A letter sent around to the state-run health service said there would be a “significant reduction in weekly supply available from manufacturers” from the week commencing March 29, meaning volumes for first doses will be significantly constrained.

Manufacturers predict this will continue for four weeks due to cuts in national inbound vaccines supply, it continued.

The letter said vaccination centres should “ensure no further appointments” for April, and focus on ensuring all those in the most vulnerable categories had received their first shot, and those who have already received a dose got a second.

Sterling fell to its lowest of the day versus the dollar in the hour after the letter was first reported, dipping from $1.3882 to $1.3849 but remaining within the range seen in recent days.

Hancock did not say why there would be a reduction in supplies. Britain has been issuing shots made by AstraZeneca and Pfizer-BioNTech , both of which have struggled to meet EU contract obligations due to production issues.

The BBC’s political editor Laura Kuenssberg said the problem was a result of fewer AstraZeneca vaccines being available than expected, and that it was “more significant” than previous lumps in supplies. AstraZeneca declined to comment.

The opposition Labour Party was critical of the government’s response, saying dismissing concerns about the supply issues was not good enough.

The problem comes as Brussels threatens to ban exports of COVID-19 vaccines to Britain to safeguard scarce doses for its own citizens as it aired frustration over a lack of deliveries moving from AstraZeneca in Britain to Europe.

Hancock said the vaccine had been developed with funding from the British government and Britain had a legal right to the shots.

“We set up the supply chain, not just here in the UK but indeed, we helped set up the supply chain in the EU,” he said.

“We legally signed a contract for delivery of the first 100 million doses here for people in the UK, as you would expect, both to ensure that people in the UK can get their jab and also because this is a UK-funded, UK-delivered vaccine.”

Gallery

Comments - share your knowledge and experience

Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.

Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here.

No Comments, yet

Please peer review 3 community comments before your comment can be posted